The 3rd NCCR RNA & Disease summer school is planned to take place in 2019.
2nd NCCR RNA & Disease Summer School
“RNA & RNP architecture: from structure to function to disease”
August 28. - September 1. 2017 - Saas-Fee - Switzerland
From August 28th to September 1st 2017, the NCCR RNA & Disease organised its second Summer School in Saas-Fee, Switzerland. The five-day Summer School “RNA & RNP architecture: from structure to function to disease” allowed students and postdoctoral researchers to expand their knowledge in the field of RNA structure and its importance in function and disease. A one-day workshop dedicated to RNA techniques provided the unique opportunity for participants to gain deep insights into the state of the art methodologies in the field. The program consisted of keynote presentations from invited speakers, discussion groups and presentations from participating students and postdocs.
1st NCCR RNA & Disease Summer School
“RNA as Target and Drug”
August 24th -28th 2015 in Saas-Fee - Switzerland
The NCCR RNA & Disease actively promotes the education of young researchers. To stimulate exchange between young researchers and leading scientists in the field of RNA Biology and RNA therapeutics, we organized the 1st NCCR RNA & Disease Summer School covering the topic “RNA as Target and Drug”. The Summer School provided the opportunity to share ideas and learn about the RNA molecule both as target for therapies and as a drug, interactively with internationally renowned scientists from academia and industry.
The first NCCR RNA & Disease Summer School took place from August 24th to 28th 2015 in Saas-Fee, Switzerland. The program consisted of keynote presentations from invited speakers, discussion panels and presentations from participating PhD students, postdocs, and MSc students.
Speakers of the 1st Summer School
- Akin Akinc - Alnylam Pharmaceuticals, Cambridge, USA
- Suzanne Braga - Medical Genetics, PPM, Bern, Switzerland
- Serge Braun - AFM-Théléthon, France
- Thomas A. Cooper - Baylor College of Medicine, Houston, USA
- Jonathan Hall - ETH Zürich, Switzerland
- Ryszard Kole - Sarepta Therapeutics, Cambridge, USA
- Erich Koller - Roche, Basel, Switzerland
- Daniel Schümperli - University of Bern, Switzerland
- Markus Stoffel - ETH Zürich, Switzerland
- Andrea Ventura - Memorial Sloan Kettering Cancer Center, New York, USA
- Dimitrios Zisoulis - Regulus Therapeutics, San Diego, USA